Clinical trials: Pembrolizumab
Esophageal Cancer, Squamous Cell Esophagus Cancer
Pembrolizumab in Refractory Advanced Esophageal Cancer
This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab
- Conditions
- Esophageal Cancer, Squamous Cell Esophagus Cancer, Adenocarcinoma Esophagus
- Trial name
- NCT02971956
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Chest Wall Tumor
Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer
This is a Phase II single center, open-label, non-randomized study in patients with locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall.
- Trial name
- PERICLES (NCT03971045)
- Testing
- Pembrolizumab
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- European Institute of Oncology
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
This phase II trial studies how well tavokinogene telseplasmid with electroporation (tavo-EP), pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03823131
- Testing
- ImmunoPulse, Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Chase Heaton, MD
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or…
- Trial name
- NCT05363631
- Testing
- Selenomethionine (SLM), Axitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fernando Maciel Barbosa
Basal Cell Carcinoma of the Head and Neck
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
The purpose of this study is to evaluate anti-PD-1 Neoadjuvant therapy in Basal cell carcinoma to provide a better outcome when administered prior to surgery and provide a therapeutic strategy to avoid surgery altogether.
- Trial name
- NCT04323202
- Testing
- Pembrolizumab, Tissue collection
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Refractory Acute Myeloid Leukemia
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
This is an open label, single-arm, pilot trial to evaluate the immune effects, safety and tolerability of pembrolizumab in subjects newly diagnosed with acute myeloid leukemia (AML) who have persistent leukemia after induction…
- Trial name
- NCT03291353
- Testing
- pembrolizumab
- Where
- United States
- Sponsor
- Michael Boyiadzis
Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
This phase I/II trial investigates the best dose and effect of alisertib in combination with pembrolizumab in treating patients with Rb-deficient head and neck squamous cell cancer. Alisertib may help block the growth of cancer..
- Trial name
- NCT04555837
- Testing
- Alisertib, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
This is a Phase 2 trial consisting of 24 patients receiving the combination of dabrafenib + trametinib + pembrolizumab in 3 different dosing schemes and 8 patients receiving pembrolizumab standard monotherapy.
- Trial name
- IMPemBra (NCT02625337)
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site)…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma
- Trial name
- NCT05764395
- Testing
- Rigosertib, Pembrolizumab, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
The main purpose of this study is to see how well the experimental drug pembrolizumab (MK-3475) works in people with oligometastatic NSCLC who have already had treatment for their disease.
- Trial name
- NCT02316002
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Carcinoma, Squamous Cell, Anorectal Cancer
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
- Trial name
- NCT06669572
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Advanced Head and Neck Squamous Cell Carcinoma
PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
The usual approach for patients who are not in a study is treatment with pembrolizumab, a type of immunotherapy drug. Immunotherapy works by allowing the immune system to detect your cancer and reactivate the immune response.
- Trial name
- PROMOTE-HN (NCT05743777)
- Testing
- Pembrolizumab, MET-4
- Sponsor
- Canadian Cancer Trials Group
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or…
- Trial name
- PEARLS (NCT02504372)
- Testing
- Pembrolizumab
- Volunteers
- 1,177 people
- Sponsor
- Merck Sharp & Dohme LLC
Hodgkin Lymphoma
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of participants with relapsed or refractory Classical Hodgkin Lymphoma.
- Trial name
- NCT02684292
- Testing
- pembrolizumab, brentuximab vedotin
- Volunteers
- 304 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Neoplasm
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the…
- Trial name
- NCT06780098
- Testing
- R-DXD, I-DXD, Docetaxel
- Where
- 46 sites in United States, Chile and 9 more
- Volunteers
- 144 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Gastric cancer is one of the major health problems worldwide, and one of the leading cause of death especially in Asia. Though the cytotoxic chemotherapy is the main treatment option, newer and molecularly targeted agents are…
- Trial name
- NCT02901301
- Testing
- Pembrolizumab, Trastuzumab, Capecitabine
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Yonsei University
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is one of the common malignant tumors in the world. More than 60% of HNSCC patients are locally advanced when first diagnosed.
- Trial name
- NCT06814067
- Testing
- Pembrolizumab, Ivonescimab, Surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic, High Immune Infiltrate
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
About 85% of cases of non-metastatic colorectal cancer (CRC) are related to chromosomal instability and have a proficient DNA Mismatch-Repair system (pMMR); which are also called CRC with microsatellite stability (MSS).
- Conditions
- Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
- Trial name
- POCHI (NCT04262687)
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- 88 sites in France
- Volunteers
- 55 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Breast Cancer, Metastatic Triple Negative
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on the patient and areas of cancer in their body that did not receive radiation therapy.
- Trial name
- NCT02730130
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.